This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Belgian anti-trust regulators are probing Roche over concerns that the drug company took steps to delay the entry of biosimilar versions of two of its cancer medicines. The agency also maintained Roche disseminated “erroneous information” about using biosimilars in combination therapy.
This certification highlights sustainable practices in operations and maintenance and marks a significant achievement for Lupin, making it one of the first Indian pharmaceuticalcompanies to reach this milestone. The facility was designed as a LEED Platinum-certified building when it was inaugurated in 2017.
The Association of the British Pharmaceutical Industry (ABPI) has welcomed the proposed changes, highlighting their potential to support talent development in areas such as advanced manufacturing, digital skills, and emerging biotechnologies. billion in 2017/18 to 2.5 billion in 2023/24.
We continue to support our clients drug discovery by continuously evolving our pharmaceuticalcompany-derived drug discovery platform by incorporating cutting-edge technologies. The companys approach features multi-step high-throughput synthesis technology and quick ADME problem-solving.
His first known founding effort was Threshold Pharmaceuticals, where he served as CEO from 2001 to 2006, according to LinkedIn, and which merged with Molecular Templates in 2017. He was also CEO of La Jolla PharmaceuticalCompany from 2011 to 2019, leading the development of a blood pressure drug that failed to meet sales expectations.
billion takeover bid for Verve Therapeutics, upgrading a collaboration between the two companies that dates back to 2023. billion takeover bid for Verve Therapeutics, upgrading a collaboration between the two companies that dates back to 2023.
Separately, the drugmaker agreed to pay $25 million to settle charges of participating in a price-fixing scheme with other generic companies. At the same time, Teva steadily raised the price of its drug by thousands of dollars. At the same time, Teva steadily raised the price of its drug by thousands of dollars.
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content